Compare AIP & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIP | VSTM |
|---|---|---|
| Founded | 2003 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 677.1M | 723.8M |
| IPO Year | 2021 | 2012 |
| Metric | AIP | VSTM |
|---|---|---|
| Price | $17.25 | $7.79 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $16.30 | $13.38 |
| AVG Volume (30 Days) | 518.2K | ★ 2.0M |
| Earning Date | 02-17-2026 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $65,931,000.00 | $13,379,000.00 |
| Revenue This Year | $20.67 | $208.54 |
| Revenue Next Year | $20.20 | $251.40 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 20.45 | ★ 33.79 |
| 52 Week Low | $5.46 | $4.01 |
| 52 Week High | $19.85 | $11.25 |
| Indicator | AIP | VSTM |
|---|---|---|
| Relative Strength Index (RSI) | 58.26 | 45.07 |
| Support Level | $16.17 | $6.68 |
| Resistance Level | $17.66 | $8.88 |
| Average True Range (ATR) | 0.79 | 0.55 |
| MACD | 0.05 | 0.02 |
| Stochastic Oscillator | 84.15 | 52.73 |
Arteris Inc is a provider of semiconductor system IP, including interconnect and other intellectual property, (collectively, System IP) technology. Its IP technology manages the on-chip communications and IP block deployments in System-on-Chip (SoC) semiconductors and systems of chiplets. Its proprietary System IP solutions achieve this by connecting client IP blocks such as processors, memories, artificial intelligence/machine learning (AI/ML) accelerators, graphics subsystems, safety and security, and other input/output subsystems (I/Os) via multiple Network-on-Chips (NoCs). The company operates in Americas, Asia Pacific and Europe, Middle East, out of which it derives maximum profit from Asia Pacific.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.